Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Mature
Primary summary from verified readiness
- Confidence
- 78% · fresh
- Computed at
- 2026-10-21T06:32:34.918204+00:00
- Claimed
- 92
- Reported
- 92
- Verified
- 85
- Gap
- +7
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Critical
Decision
What the current evidence supports
Human editorial judgment · 2026-10-21
Proceed with caution
- Why
- An FDA and Japan-approved first-in-class ASO delivered a placebo-controlled 19-20% functional cure in two replicate phase 3 trials, with 26% in the HBsAg <=1000 IU/mL subgroup, against about 1-4% with standard care. It carries a boxed warning, needs a companion diagnostic and a narrow eligible population, and long-term durability is unproven, so evidence is strong for the regulated indication but not for broad use.
- Next
- Track GSK's US launch, price and label uptake, B-Sure durability data, and EU and China decisions; benchmark against HBV siRNA and epigenetic-silencer programs (including TUNE-401 and CRMA-1001 already in the register).
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 2
- Tier 2
- 4
- Tier 3
- 0
- Supports
- 4
- Contradicts
- 1
- Context
- 1
- Latest observed
- 2026-10-20
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-10-21 Initial recorded band: mature.